Krystal Biotech shares up sharply after it logs revenue from newly approved product
It's a gene-therapy treatment of a rare skin disease called dystrophic epidermolysis bullosa (DEB). (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 26, 2024 Category: Biotechnology Authors: Paul J. Gough Source Type: news
New Gene Therapy for Skin Wounds Improved Vision in Young Boy
(MedPage Today) -- Ophthalmic administration of beremagene geperpavec (B-VEC; Vyjuvek) improved visual acuity in a young patient with cicatrizing conjunctivitis due to dystrophic epidermolysis bullosa, researchers reported.
With treatment with... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 8, 2024 Category: Dermatology Source Type: news
Review Spotlights Effects of Epidermolysis Bullosa on Bones Review Spotlights Effects of Epidermolysis Bullosa on Bones
Researchers summarized recommendations from 13 published studies.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 17, 2024 Category: Dermatology Tags: Dermatology Source Type: news
FDA Approves Filsuvez (birch triterpenes) Topical Gel for the Treatment of Epidermolysis Bullosa
BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2023 Category: Drugs & Pharmacology Source Type: news
Topical Treatment for Epidermolysis Bullosa Wins FDA Approval
(MedPage Today) -- The FDA approved birch triterpenes (Filsuvez) topical gel for the treatment of epidermolysis bullosa (EB), Chiesi Global Rare Diseases announced on Tuesday.
The approval stipulates use for partial thickness wounds in adults... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 19, 2023 Category: American Health Source Type: news
Touch of death: Man, 28, with rare skin condition that leaves agonizing wounds at the slightest graze and could kill him in his 30s says even 'walking and eating are a constant battle'
Victor Hugo Quiroz, 28, was diagnosed with Dystrophic Epidermolysis Bullosa (EB) at birth, a genetic condition that has left him with extremely fragile skin and webbed hands and feet. (Source: the Mail online | Health)
Source: the Mail online | Health - December 14, 2023 Category: Consumer Health News Source Type: news
Heartbreaking vow of boy, 18, with rare 'butterfly skin' disease as he's given days to live - after planning his own funeral aged 13 - as he tells his mother: 'I'm so sorry. I'll try to fight it'
Rhys Williams, 18, from Bolton, was born with a severe skin condition called epidermolysis bullosa (EB), which means his skin is so thin that the tiniest impact could be life-altering. (Source: the Mail online | Health)
Source: the Mail online | Health - December 11, 2023 Category: Consumer Health News Source Type: news
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first time • VYJUVEK received Orphan Drug Designation and PRIME designation from the EMA PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- (the "Company") KRYS, a…#deb #vyjuvek #ema #pittsburgh #krys #maa #sumakrishnan #researchdevelopment #krystalbiotech #epidermolysisbullosa (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2023 Category: Consumer Health News Source Type: news
Oleogel-S10 Reduces Daily Dressing Need in EB Study Oleogel-S10 Reduces Daily Dressing Need in EB Study
Oleogel-S10 reduced the need for daily dressing changes compared with a control gel in patients with epidermolysis bullosa, according to a further analysis of data from the phase 3 EASE study.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 24, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 26, 2023 Category: Drugs & Pharmacology Source Type: news
Breakthrough In Gene Therapy: Epidermolysis Bullosa
In a groundbreaking development, gene therapy delivered through eyedrops has restored the sight of a teenager who has been legally blind for most of his life. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 17, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Camp for Kids With Skin Disorders Marks 30th Anniversary Camp for Kids With Skin Disorders Marks 30th Anniversary
The camp, sponsored by the American Academy of Dermatology, accepts youth with conditions ranging from eczema and psoriasis to vitiligo, alopecia, epidermolysis bullosa, and ichthyosis.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 25, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Progress Seen in Substantially Improving Treatment of EB Progress Seen in Substantially Improving Treatment of EB
The promise of gene, cell, and protein therapies for epidermolysis bullosa has been pursued for years, but accelerated progress is translating into new therapies now available or in phase 3 trials.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 24, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
First Ever Topical Gene Therapy Approved For “Butterfly Disease” Children
Topical gene therapy VYJUVEK approved Butterfly Disease Epidermolysis Bullosa Beremagene Geperpavec (B-VEC) EBRP (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 24, 2023 Category: Pharmaceuticals Authors: Greg Licholai, MD, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news
U.S. FDA approves Krystal Biotech's skin-disorder gene therapy
The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's (KRYS.O) first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in afternoon trading. Patients with the rare dystrophic epidermolysis bullosa disorder suffer from open…#krystalbiotechinc #vyjuvek #krystalbiotech #krishkrishnan #fda #krishnan #krystal #bengaluru (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2023 Category: Consumer Health News Source Type: news
